Skip to content

To explore the mechanism of acupuncture and moxibustion artificial cycle therapy to improve follicular quality of polycystic ovary syndrome based on histone acetylation modified post transcriptional regulation

To explore the mechanism of acupuncture and moxibustion artificial cycle therapy to improve follicular quality of polycystic ovary syndrome based on histone acetylation modified post transcriptional regulation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092398
Enrollment
Unknown
Registered
2024-11-15
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovary syndrome

Interventions

Treatment Group:Acupuncture and moxibustion+Letrozole
Control Group:Placebo needle+Letrozole

Sponsors

Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1.Conform to the diagnostic criteria of western medicine and traditional Chinese medicine; 2.The age is between 20 and 40; 3.Sign the informed consent form voluntarily.

Exclusion criteria

Exclusion criteria: 1. Exclude patients with hyperandrogenism caused by other reasons, such as Cushing syndrome, late-onset congenital adrenal hyperplasia, androgen-secreting ovarian and adrenal tumors, etc., and other diseases that cause ovulation dysfunction, such as pituitary or hypothalamic amenorrhea, hyperprolactinemia, premature ovarian failure, etc.; 2. Exclude organic diseases or other endocrine diseases; 3. Patients with severe liver and kidney, cardiovascular and cerebrovascular diseases, hematopoietic system dysfunction and mental illness; 4. Patients who have taken hormones and anticoagulant drugs in the past 3 months, or who have participated in other clinical experiments; 5. Those under the age of 20 or over the age of 40; 6. Those who do not meet the inclusion criteria or have incomplete information that affects the judgment; 7. Those who cannot adhere to the course of treatment, withdraw halfway or lose follow-up; 8. Those who have serious complications in the test.

Design outcomes

Primary

MeasureTime frame
Pregnancy rate;Ovulation rate;Early miscarriage rate;

Secondary

MeasureTime frame
TCM symptom score;Glycolipid metabolism;Endocrine metabolism;Histone acetylation modification;Mitochondrial oxidative stress;Akt/mTOR/Fox0 signaling pathway;

Countries

China

Contacts

Public ContactXu Jinbang

Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University

75157335@qq.com+86 135 5995 8096

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026